Maxim Group Reiterates “Buy” Rating for Coherus Biosciences (NASDAQ:CHRS)

Share on StockTwits

Maxim Group reaffirmed their buy rating on shares of Coherus Biosciences (NASDAQ:CHRS) in a research note released on Wednesday, AnalystRatings.com reports. They currently have a $25.00 price target on the biotechnology company’s stock.

“Coherus announced preliminary net sales on UDENYCA of $79M-$84M suggesting swift uptake. This is more than double the 1Q19 figure of $37M. Despite the increase in sales, CHRS shares were down over 13% yesterday.”,” Maxim Group’s analyst commented.

CHRS has been the topic of several other research reports. BidaskClub downgraded shares of Walgreens Boots Alliance from a sell rating to a strong sell rating in a report on Monday, June 24th. Zacks Investment Research downgraded shares of HEXO from a hold rating to a sell rating in a report on Wednesday, May 15th. HC Wainwright upped their price objective on shares of Applied Genetic Technologies from $5.75 to $12.00 and gave the company a buy rating in a report on Tuesday, May 7th. Robert W. Baird set a $28.00 price objective on shares of Coherus Biosciences and gave the company a buy rating in a report on Wednesday, June 19th. Finally, ValuEngine downgraded shares of Zymeworks from a buy rating to a hold rating in a report on Saturday, May 18th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $29.14.

CHRS stock opened at $19.23 on Wednesday. Coherus Biosciences has a twelve month low of $8.32 and a twelve month high of $23.43. The company’s fifty day moving average price is $20.10.

Coherus Biosciences (NASDAQ:CHRS) last issued its earnings results on Thursday, May 9th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.45) by $0.16. The company had revenue of $37.10 million for the quarter, compared to analysts’ expectations of $36.83 million. On average, equities research analysts expect that Coherus Biosciences will post -0.46 EPS for the current fiscal year.

In other news, CEO Dennis M. Lanfear sold 32,398 shares of the business’s stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $19.49, for a total value of $631,437.02. Following the transaction, the chief executive officer now owns 125,017 shares of the company’s stock, valued at $2,436,581.33. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director James Healy sold 360,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 2nd. The shares were sold at an average price of $22.30, for a total value of $8,028,000.00. Following the completion of the transaction, the director now directly owns 92 shares in the company, valued at approximately $2,051.60. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,174,224 shares of company stock worth $25,317,332. Insiders own 18.20% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the stock. Legal & General Group Plc grew its holdings in Coherus Biosciences by 12.3% during the fourth quarter. Legal & General Group Plc now owns 9,095 shares of the biotechnology company’s stock worth $82,000 after acquiring an additional 998 shares during the period. DekaBank Deutsche Girozentrale grew its holdings in Coherus Biosciences by 20.3% during the first quarter. DekaBank Deutsche Girozentrale now owns 21,300 shares of the biotechnology company’s stock worth $426,000 after acquiring an additional 3,600 shares during the period. Hound Partners LLC grew its holdings in Coherus Biosciences by 0.3% during the fourth quarter. Hound Partners LLC now owns 2,016,827 shares of the biotechnology company’s stock worth $18,252,000 after acquiring an additional 6,551 shares during the period. SG Americas Securities LLC acquired a new position in Coherus Biosciences during the first quarter worth $108,000. Finally, Bank of New York Mellon Corp boosted its position in Coherus Biosciences by 4.1% during the fourth quarter. Bank of New York Mellon Corp now owns 222,542 shares of the biotechnology company’s stock worth $2,013,000 after purchasing an additional 8,766 shares in the last quarter. 99.18% of the stock is currently owned by hedge funds and other institutional investors.

About Coherus Biosciences

Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States.

See Also: 52-Week High/Low

Analyst Recommendations for Coherus Biosciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.